A Trial of the Irradiance Level of Phototherapy for Neonatal Jaundice
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03055481|
Recruitment Status : Unknown
Verified January 2018 by Yoshiaki Sato, Nagoya University.
Recruitment status was: Recruiting
First Posted : February 16, 2017
Last Update Posted : January 9, 2018
|Condition or disease||Intervention/treatment||Phase|
|Neonatal Jaundice||Other: High irradiance level of phototherapy Other: Low irradiance level of phototherapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Multicenter Non-inferiority Randomized Controlled Trial of the Irradiance Level of Phototherapy for Neonatal Jaundice|
|Actual Study Start Date :||July 1, 2017|
|Estimated Primary Completion Date :||February 20, 2019|
|Estimated Study Completion Date :||February 20, 2020|
Active Comparator: High level irradiation
High level irradiation: the target irradiance level is 30-35uW per square centimeter per nano-meter of wavelength.
Other: High irradiance level of phototherapy
High irradiance level of phototherapy: the target irradiance level is 30-35uW per square centimeter per nanometer of wavelength.
Experimental: Low level irradiation
Low level irradiation: the target irradiance level is 12-15uW per square centimeter per nano-meter of wavelength.
Other: Low irradiance level of phototherapy
Low irradiance level of phototherapy: the target irradiance level is 12-15uW per square centimeter per nanometer of wavelength
- Retreatment rate of neonatal jaundice [ Time Frame: one month ]Treatment of neonatal jaundice again after finishing phototherapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03055481
|Contact: Kazuhiro Horiba, MDfirstname.lastname@example.org|
|Contact: Yoshiaki Sato, MD,PhDemail@example.com|
|Anjo Kosei Hospital||Active, not recruiting|
|Anjo, Aichi, Japan, 446-8602|
|Handa City Hospital||Recruiting|
|Handa, Aichi, Japan, 475-8599|
|Hekinan Municipal Hospital||Recruiting|
|Hekinan, Aichi, Japan, 447-8502|
|Kasugai Municipal Hospital||Recruiting|
|Kasugai, Aichi, Japan, 486-8510|
|Japan Red Cross Nagoya Daiichi Hospital||Recruiting|
|Nagoya, Aichi, Japan, 453-8511|
|Nagoya University Hospital||Recruiting|
|Nagoya, Aichi, Japan, 466-8550|
|Contact: Yoshiaki Sato +81-52-744-2294 firstname.lastname@example.org|
|Contact: Kazuhiro Horiba +81-52-744-2294 email@example.com|
|TOYOTA Memorial Hospital||Recruiting|
|Toyota, Aichi, Japan, 471-8513|
|Ogaki Municipal Hospital||Recruiting|
|Ogaki, Gifu, Japan, 503-8502|